Global DTaP and Tdap Vaccines Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global DTaP and Tdap Vaccines market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.
Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.
The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%–85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the DTaP and Tdap Vaccines industry chain, the market status of Adult (DTaP, Td), Pediatric (DTaP, Td), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of DTaP and Tdap Vaccines.
Regionally, the report analyzes the DTaP and Tdap Vaccines markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global DTaP and Tdap Vaccines market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the DTaP and Tdap Vaccines market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the DTaP and Tdap Vaccines industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., DTaP, Td).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the DTaP and Tdap Vaccines market.
Regional Analysis: The report involves examining the DTaP and Tdap Vaccines market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the DTaP and Tdap Vaccines market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to DTaP and Tdap Vaccines:
Company Analysis: Report covers individual DTaP and Tdap Vaccines manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards DTaP and Tdap Vaccines This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Adult, Pediatric).
Technology Analysis: Report covers specific technologies relevant to DTaP and Tdap Vaccines. It assesses the current state, advancements, and potential future developments in DTaP and Tdap Vaccines areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the DTaP and Tdap Vaccines market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
DTaP and Tdap Vaccines market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe DTaP and Tdap Vaccines product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of DTaP and Tdap Vaccines, with price, sales, revenue and global market share of DTaP and Tdap Vaccines from 2019 to 2024.
Chapter 3, the DTaP and Tdap Vaccines competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the DTaP and Tdap Vaccines breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and DTaP and Tdap Vaccines market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of DTaP and Tdap Vaccines.
Chapter 14 and 15, to describe DTaP and Tdap Vaccines sales channel, distributors, customers, research findings and conclusion.
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.
Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.
The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%–85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the DTaP and Tdap Vaccines industry chain, the market status of Adult (DTaP, Td), Pediatric (DTaP, Td), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of DTaP and Tdap Vaccines.
Regionally, the report analyzes the DTaP and Tdap Vaccines markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global DTaP and Tdap Vaccines market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the DTaP and Tdap Vaccines market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the DTaP and Tdap Vaccines industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., DTaP, Td).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the DTaP and Tdap Vaccines market.
Regional Analysis: The report involves examining the DTaP and Tdap Vaccines market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the DTaP and Tdap Vaccines market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to DTaP and Tdap Vaccines:
Company Analysis: Report covers individual DTaP and Tdap Vaccines manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards DTaP and Tdap Vaccines This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Adult, Pediatric).
Technology Analysis: Report covers specific technologies relevant to DTaP and Tdap Vaccines. It assesses the current state, advancements, and potential future developments in DTaP and Tdap Vaccines areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the DTaP and Tdap Vaccines market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
DTaP and Tdap Vaccines market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- DTaP
- Td
- Tdap
- Adult
- Pediatric
- Sanofi Pasteur
- GlaxoSmithKline
- Protein Sciences Corporation
- Novartis AG
- Seqirus
- Merck Sharp & Dohme Corp
- Astellas Pharma US, Inc
- Pfizer Inc
- Johnson & Johnson
- Lanzhou Institute of Biological Products Co., Ltd
- AstraZeneca
- Emergent BioSolutions Inc
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe DTaP and Tdap Vaccines product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of DTaP and Tdap Vaccines, with price, sales, revenue and global market share of DTaP and Tdap Vaccines from 2019 to 2024.
Chapter 3, the DTaP and Tdap Vaccines competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the DTaP and Tdap Vaccines breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and DTaP and Tdap Vaccines market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of DTaP and Tdap Vaccines.
Chapter 14 and 15, to describe DTaP and Tdap Vaccines sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of DTaP and Tdap Vaccines
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global DTaP and Tdap Vaccines Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 DTaP
1.3.3 Td
1.3.4 Tdap
1.4 Market Analysis by Application
1.4.1 Overview: Global DTaP and Tdap Vaccines Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Adult
1.4.3 Pediatric
1.5 Global DTaP and Tdap Vaccines Market Size & Forecast
1.5.1 Global DTaP and Tdap Vaccines Consumption Value (2019 & 2023 & 2030)
1.5.2 Global DTaP and Tdap Vaccines Sales Quantity (2019-2030)
1.5.3 Global DTaP and Tdap Vaccines Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Sanofi Pasteur
2.1.1 Sanofi Pasteur Details
2.1.2 Sanofi Pasteur Major Business
2.1.3 Sanofi Pasteur DTaP and Tdap Vaccines Product and Services
2.1.4 Sanofi Pasteur DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Sanofi Pasteur Recent Developments/Updates
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline DTaP and Tdap Vaccines Product and Services
2.2.4 GlaxoSmithKline DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 GlaxoSmithKline Recent Developments/Updates
2.3 Protein Sciences Corporation
2.3.1 Protein Sciences Corporation Details
2.3.2 Protein Sciences Corporation Major Business
2.3.3 Protein Sciences Corporation DTaP and Tdap Vaccines Product and Services
2.3.4 Protein Sciences Corporation DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Protein Sciences Corporation Recent Developments/Updates
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG DTaP and Tdap Vaccines Product and Services
2.4.4 Novartis AG DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Novartis AG Recent Developments/Updates
2.5 Seqirus
2.5.1 Seqirus Details
2.5.2 Seqirus Major Business
2.5.3 Seqirus DTaP and Tdap Vaccines Product and Services
2.5.4 Seqirus DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Seqirus Recent Developments/Updates
2.6 Merck Sharp & Dohme Corp
2.6.1 Merck Sharp & Dohme Corp Details
2.6.2 Merck Sharp & Dohme Corp Major Business
2.6.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product and Services
2.6.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Merck Sharp & Dohme Corp Recent Developments/Updates
2.7 Astellas Pharma US, Inc
2.7.1 Astellas Pharma US, Inc Details
2.7.2 Astellas Pharma US, Inc Major Business
2.7.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product and Services
2.7.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Astellas Pharma US, Inc Recent Developments/Updates
2.8 Pfizer Inc
2.8.1 Pfizer Inc Details
2.8.2 Pfizer Inc Major Business
2.8.3 Pfizer Inc DTaP and Tdap Vaccines Product and Services
2.8.4 Pfizer Inc DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Pfizer Inc Recent Developments/Updates
2.9 Johnson & Johnson
2.9.1 Johnson & Johnson Details
2.9.2 Johnson & Johnson Major Business
2.9.3 Johnson & Johnson DTaP and Tdap Vaccines Product and Services
2.9.4 Johnson & Johnson DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Johnson & Johnson Recent Developments/Updates
2.10 Lanzhou Institute of Biological Products Co., Ltd
2.10.1 Lanzhou Institute of Biological Products Co., Ltd Details
2.10.2 Lanzhou Institute of Biological Products Co., Ltd Major Business
2.10.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product and Services
2.10.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
2.11 AstraZeneca
2.11.1 AstraZeneca Details
2.11.2 AstraZeneca Major Business
2.11.3 AstraZeneca DTaP and Tdap Vaccines Product and Services
2.11.4 AstraZeneca DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 AstraZeneca Recent Developments/Updates
2.12 Emergent BioSolutions Inc
2.12.1 Emergent BioSolutions Inc Details
2.12.2 Emergent BioSolutions Inc Major Business
2.12.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product and Services
2.12.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Emergent BioSolutions Inc Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: DTAP AND TDAP VACCINES BY MANUFACTURER
3.1 Global DTaP and Tdap Vaccines Sales Quantity by Manufacturer (2019-2024)
3.2 Global DTaP and Tdap Vaccines Revenue by Manufacturer (2019-2024)
3.3 Global DTaP and Tdap Vaccines Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of DTaP and Tdap Vaccines by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 DTaP and Tdap Vaccines Manufacturer Market Share in 2023
3.4.2 Top 6 DTaP and Tdap Vaccines Manufacturer Market Share in 2023
3.5 DTaP and Tdap Vaccines Market: Overall Company Footprint Analysis
3.5.1 DTaP and Tdap Vaccines Market: Region Footprint
3.5.2 DTaP and Tdap Vaccines Market: Company Product Type Footprint
3.5.3 DTaP and Tdap Vaccines Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global DTaP and Tdap Vaccines Market Size by Region
4.1.1 Global DTaP and Tdap Vaccines Sales Quantity by Region (2019-2030)
4.1.2 Global DTaP and Tdap Vaccines Consumption Value by Region (2019-2030)
4.1.3 Global DTaP and Tdap Vaccines Average Price by Region (2019-2030)
4.2 North America DTaP and Tdap Vaccines Consumption Value (2019-2030)
4.3 Europe DTaP and Tdap Vaccines Consumption Value (2019-2030)
4.4 Asia-Pacific DTaP and Tdap Vaccines Consumption Value (2019-2030)
4.5 South America DTaP and Tdap Vaccines Consumption Value (2019-2030)
4.6 Middle East and Africa DTaP and Tdap Vaccines Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
5.2 Global DTaP and Tdap Vaccines Consumption Value by Type (2019-2030)
5.3 Global DTaP and Tdap Vaccines Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
6.2 Global DTaP and Tdap Vaccines Consumption Value by Application (2019-2030)
6.3 Global DTaP and Tdap Vaccines Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
7.2 North America DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
7.3 North America DTaP and Tdap Vaccines Market Size by Country
7.3.1 North America DTaP and Tdap Vaccines Sales Quantity by Country (2019-2030)
7.3.2 North America DTaP and Tdap Vaccines Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
8.2 Europe DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
8.3 Europe DTaP and Tdap Vaccines Market Size by Country
8.3.1 Europe DTaP and Tdap Vaccines Sales Quantity by Country (2019-2030)
8.3.2 Europe DTaP and Tdap Vaccines Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific DTaP and Tdap Vaccines Market Size by Region
9.3.1 Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific DTaP and Tdap Vaccines Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
10.2 South America DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
10.3 South America DTaP and Tdap Vaccines Market Size by Country
10.3.1 South America DTaP and Tdap Vaccines Sales Quantity by Country (2019-2030)
10.3.2 South America DTaP and Tdap Vaccines Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa DTaP and Tdap Vaccines Market Size by Country
11.3.1 Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa DTaP and Tdap Vaccines Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 DTaP and Tdap Vaccines Market Drivers
12.2 DTaP and Tdap Vaccines Market Restraints
12.3 DTaP and Tdap Vaccines Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of DTaP and Tdap Vaccines and Key Manufacturers
13.2 Manufacturing Costs Percentage of DTaP and Tdap Vaccines
13.3 DTaP and Tdap Vaccines Production Process
13.4 DTaP and Tdap Vaccines Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 DTaP and Tdap Vaccines Typical Distributors
14.3 DTaP and Tdap Vaccines Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of DTaP and Tdap Vaccines
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global DTaP and Tdap Vaccines Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 DTaP
1.3.3 Td
1.3.4 Tdap
1.4 Market Analysis by Application
1.4.1 Overview: Global DTaP and Tdap Vaccines Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Adult
1.4.3 Pediatric
1.5 Global DTaP and Tdap Vaccines Market Size & Forecast
1.5.1 Global DTaP and Tdap Vaccines Consumption Value (2019 & 2023 & 2030)
1.5.2 Global DTaP and Tdap Vaccines Sales Quantity (2019-2030)
1.5.3 Global DTaP and Tdap Vaccines Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Sanofi Pasteur
2.1.1 Sanofi Pasteur Details
2.1.2 Sanofi Pasteur Major Business
2.1.3 Sanofi Pasteur DTaP and Tdap Vaccines Product and Services
2.1.4 Sanofi Pasteur DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Sanofi Pasteur Recent Developments/Updates
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline DTaP and Tdap Vaccines Product and Services
2.2.4 GlaxoSmithKline DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 GlaxoSmithKline Recent Developments/Updates
2.3 Protein Sciences Corporation
2.3.1 Protein Sciences Corporation Details
2.3.2 Protein Sciences Corporation Major Business
2.3.3 Protein Sciences Corporation DTaP and Tdap Vaccines Product and Services
2.3.4 Protein Sciences Corporation DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Protein Sciences Corporation Recent Developments/Updates
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG DTaP and Tdap Vaccines Product and Services
2.4.4 Novartis AG DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Novartis AG Recent Developments/Updates
2.5 Seqirus
2.5.1 Seqirus Details
2.5.2 Seqirus Major Business
2.5.3 Seqirus DTaP and Tdap Vaccines Product and Services
2.5.4 Seqirus DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Seqirus Recent Developments/Updates
2.6 Merck Sharp & Dohme Corp
2.6.1 Merck Sharp & Dohme Corp Details
2.6.2 Merck Sharp & Dohme Corp Major Business
2.6.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product and Services
2.6.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Merck Sharp & Dohme Corp Recent Developments/Updates
2.7 Astellas Pharma US, Inc
2.7.1 Astellas Pharma US, Inc Details
2.7.2 Astellas Pharma US, Inc Major Business
2.7.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product and Services
2.7.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Astellas Pharma US, Inc Recent Developments/Updates
2.8 Pfizer Inc
2.8.1 Pfizer Inc Details
2.8.2 Pfizer Inc Major Business
2.8.3 Pfizer Inc DTaP and Tdap Vaccines Product and Services
2.8.4 Pfizer Inc DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Pfizer Inc Recent Developments/Updates
2.9 Johnson & Johnson
2.9.1 Johnson & Johnson Details
2.9.2 Johnson & Johnson Major Business
2.9.3 Johnson & Johnson DTaP and Tdap Vaccines Product and Services
2.9.4 Johnson & Johnson DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Johnson & Johnson Recent Developments/Updates
2.10 Lanzhou Institute of Biological Products Co., Ltd
2.10.1 Lanzhou Institute of Biological Products Co., Ltd Details
2.10.2 Lanzhou Institute of Biological Products Co., Ltd Major Business
2.10.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product and Services
2.10.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
2.11 AstraZeneca
2.11.1 AstraZeneca Details
2.11.2 AstraZeneca Major Business
2.11.3 AstraZeneca DTaP and Tdap Vaccines Product and Services
2.11.4 AstraZeneca DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 AstraZeneca Recent Developments/Updates
2.12 Emergent BioSolutions Inc
2.12.1 Emergent BioSolutions Inc Details
2.12.2 Emergent BioSolutions Inc Major Business
2.12.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product and Services
2.12.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Emergent BioSolutions Inc Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: DTAP AND TDAP VACCINES BY MANUFACTURER
3.1 Global DTaP and Tdap Vaccines Sales Quantity by Manufacturer (2019-2024)
3.2 Global DTaP and Tdap Vaccines Revenue by Manufacturer (2019-2024)
3.3 Global DTaP and Tdap Vaccines Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of DTaP and Tdap Vaccines by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 DTaP and Tdap Vaccines Manufacturer Market Share in 2023
3.4.2 Top 6 DTaP and Tdap Vaccines Manufacturer Market Share in 2023
3.5 DTaP and Tdap Vaccines Market: Overall Company Footprint Analysis
3.5.1 DTaP and Tdap Vaccines Market: Region Footprint
3.5.2 DTaP and Tdap Vaccines Market: Company Product Type Footprint
3.5.3 DTaP and Tdap Vaccines Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global DTaP and Tdap Vaccines Market Size by Region
4.1.1 Global DTaP and Tdap Vaccines Sales Quantity by Region (2019-2030)
4.1.2 Global DTaP and Tdap Vaccines Consumption Value by Region (2019-2030)
4.1.3 Global DTaP and Tdap Vaccines Average Price by Region (2019-2030)
4.2 North America DTaP and Tdap Vaccines Consumption Value (2019-2030)
4.3 Europe DTaP and Tdap Vaccines Consumption Value (2019-2030)
4.4 Asia-Pacific DTaP and Tdap Vaccines Consumption Value (2019-2030)
4.5 South America DTaP and Tdap Vaccines Consumption Value (2019-2030)
4.6 Middle East and Africa DTaP and Tdap Vaccines Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
5.2 Global DTaP and Tdap Vaccines Consumption Value by Type (2019-2030)
5.3 Global DTaP and Tdap Vaccines Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
6.2 Global DTaP and Tdap Vaccines Consumption Value by Application (2019-2030)
6.3 Global DTaP and Tdap Vaccines Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
7.2 North America DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
7.3 North America DTaP and Tdap Vaccines Market Size by Country
7.3.1 North America DTaP and Tdap Vaccines Sales Quantity by Country (2019-2030)
7.3.2 North America DTaP and Tdap Vaccines Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
8.2 Europe DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
8.3 Europe DTaP and Tdap Vaccines Market Size by Country
8.3.1 Europe DTaP and Tdap Vaccines Sales Quantity by Country (2019-2030)
8.3.2 Europe DTaP and Tdap Vaccines Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific DTaP and Tdap Vaccines Market Size by Region
9.3.1 Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific DTaP and Tdap Vaccines Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
10.2 South America DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
10.3 South America DTaP and Tdap Vaccines Market Size by Country
10.3.1 South America DTaP and Tdap Vaccines Sales Quantity by Country (2019-2030)
10.3.2 South America DTaP and Tdap Vaccines Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa DTaP and Tdap Vaccines Market Size by Country
11.3.1 Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa DTaP and Tdap Vaccines Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 DTaP and Tdap Vaccines Market Drivers
12.2 DTaP and Tdap Vaccines Market Restraints
12.3 DTaP and Tdap Vaccines Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of DTaP and Tdap Vaccines and Key Manufacturers
13.2 Manufacturing Costs Percentage of DTaP and Tdap Vaccines
13.3 DTaP and Tdap Vaccines Production Process
13.4 DTaP and Tdap Vaccines Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 DTaP and Tdap Vaccines Typical Distributors
14.3 DTaP and Tdap Vaccines Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global DTaP and Tdap Vaccines Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global DTaP and Tdap Vaccines Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi Pasteur Major Business
Table 5. Sanofi Pasteur DTaP and Tdap Vaccines Product and Services
Table 6. Sanofi Pasteur DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Sanofi Pasteur Recent Developments/Updates
Table 8. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 9. GlaxoSmithKline Major Business
Table 10. GlaxoSmithKline DTaP and Tdap Vaccines Product and Services
Table 11. GlaxoSmithKline DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. GlaxoSmithKline Recent Developments/Updates
Table 13. Protein Sciences Corporation Basic Information, Manufacturing Base and Competitors
Table 14. Protein Sciences Corporation Major Business
Table 15. Protein Sciences Corporation DTaP and Tdap Vaccines Product and Services
Table 16. Protein Sciences Corporation DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Protein Sciences Corporation Recent Developments/Updates
Table 18. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 19. Novartis AG Major Business
Table 20. Novartis AG DTaP and Tdap Vaccines Product and Services
Table 21. Novartis AG DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Novartis AG Recent Developments/Updates
Table 23. Seqirus Basic Information, Manufacturing Base and Competitors
Table 24. Seqirus Major Business
Table 25. Seqirus DTaP and Tdap Vaccines Product and Services
Table 26. Seqirus DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Seqirus Recent Developments/Updates
Table 28. Merck Sharp & Dohme Corp Basic Information, Manufacturing Base and Competitors
Table 29. Merck Sharp & Dohme Corp Major Business
Table 30. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product and Services
Table 31. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Merck Sharp & Dohme Corp Recent Developments/Updates
Table 33. Astellas Pharma US, Inc Basic Information, Manufacturing Base and Competitors
Table 34. Astellas Pharma US, Inc Major Business
Table 35. Astellas Pharma US, Inc DTaP and Tdap Vaccines Product and Services
Table 36. Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Astellas Pharma US, Inc Recent Developments/Updates
Table 38. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 39. Pfizer Inc Major Business
Table 40. Pfizer Inc DTaP and Tdap Vaccines Product and Services
Table 41. Pfizer Inc DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Pfizer Inc Recent Developments/Updates
Table 43. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 44. Johnson & Johnson Major Business
Table 45. Johnson & Johnson DTaP and Tdap Vaccines Product and Services
Table 46. Johnson & Johnson DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Johnson & Johnson Recent Developments/Updates
Table 48. Lanzhou Institute of Biological Products Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 49. Lanzhou Institute of Biological Products Co., Ltd Major Business
Table 50. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product and Services
Table 51. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 53. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 54. AstraZeneca Major Business
Table 55. AstraZeneca DTaP and Tdap Vaccines Product and Services
Table 56. AstraZeneca DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 57. AstraZeneca Recent Developments/Updates
Table 58. Emergent BioSolutions Inc Basic Information, Manufacturing Base and Competitors
Table 59. Emergent BioSolutions Inc Major Business
Table 60. Emergent BioSolutions Inc DTaP and Tdap Vaccines Product and Services
Table 61. Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 62. Emergent BioSolutions Inc Recent Developments/Updates
Table 63. Global DTaP and Tdap Vaccines Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 64. Global DTaP and Tdap Vaccines Revenue by Manufacturer (2019-2024) & (USD Million)
Table 65. Global DTaP and Tdap Vaccines Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 66. Market Position of Manufacturers in DTaP and Tdap Vaccines, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 67. Head Office and DTaP and Tdap Vaccines Production Site of Key Manufacturer
Table 68. DTaP and Tdap Vaccines Market: Company Product Type Footprint
Table 69. DTaP and Tdap Vaccines Market: Company Product Application Footprint
Table 70. DTaP and Tdap Vaccines New Market Entrants and Barriers to Market Entry
Table 71. DTaP and Tdap Vaccines Mergers, Acquisition, Agreements, and Collaborations
Table 72. Global DTaP and Tdap Vaccines Sales Quantity by Region (2019-2024) & (K Units)
Table 73. Global DTaP and Tdap Vaccines Sales Quantity by Region (2025-2030) & (K Units)
Table 74. Global DTaP and Tdap Vaccines Consumption Value by Region (2019-2024) & (USD Million)
Table 75. Global DTaP and Tdap Vaccines Consumption Value by Region (2025-2030) & (USD Million)
Table 76. Global DTaP and Tdap Vaccines Average Price by Region (2019-2024) & (USD/Unit)
Table 77. Global DTaP and Tdap Vaccines Average Price by Region (2025-2030) & (USD/Unit)
Table 78. Global DTaP and Tdap Vaccines Sales Quantity by Type (2019-2024) & (K Units)
Table 79. Global DTaP and Tdap Vaccines Sales Quantity by Type (2025-2030) & (K Units)
Table 80. Global DTaP and Tdap Vaccines Consumption Value by Type (2019-2024) & (USD Million)
Table 81. Global DTaP and Tdap Vaccines Consumption Value by Type (2025-2030) & (USD Million)
Table 82. Global DTaP and Tdap Vaccines Average Price by Type (2019-2024) & (USD/Unit)
Table 83. Global DTaP and Tdap Vaccines Average Price by Type (2025-2030) & (USD/Unit)
Table 84. Global DTaP and Tdap Vaccines Sales Quantity by Application (2019-2024) & (K Units)
Table 85. Global DTaP and Tdap Vaccines Sales Quantity by Application (2025-2030) & (K Units)
Table 86. Global DTaP and Tdap Vaccines Consumption Value by Application (2019-2024) & (USD Million)
Table 87. Global DTaP and Tdap Vaccines Consumption Value by Application (2025-2030) & (USD Million)
Table 88. Global DTaP and Tdap Vaccines Average Price by Application (2019-2024) & (USD/Unit)
Table 89. Global DTaP and Tdap Vaccines Average Price by Application (2025-2030) & (USD/Unit)
Table 90. North America DTaP and Tdap Vaccines Sales Quantity by Type (2019-2024) & (K Units)
Table 91. North America DTaP and Tdap Vaccines Sales Quantity by Type (2025-2030) & (K Units)
Table 92. North America DTaP and Tdap Vaccines Sales Quantity by Application (2019-2024) & (K Units)
Table 93. North America DTaP and Tdap Vaccines Sales Quantity by Application (2025-2030) & (K Units)
Table 94. North America DTaP and Tdap Vaccines Sales Quantity by Country (2019-2024) & (K Units)
Table 95. North America DTaP and Tdap Vaccines Sales Quantity by Country (2025-2030) & (K Units)
Table 96. North America DTaP and Tdap Vaccines Consumption Value by Country (2019-2024) & (USD Million)
Table 97. North America DTaP and Tdap Vaccines Consumption Value by Country (2025-2030) & (USD Million)
Table 98. Europe DTaP and Tdap Vaccines Sales Quantity by Type (2019-2024) & (K Units)
Table 99. Europe DTaP and Tdap Vaccines Sales Quantity by Type (2025-2030) & (K Units)
Table 100. Europe DTaP and Tdap Vaccines Sales Quantity by Application (2019-2024) & (K Units)
Table 101. Europe DTaP and Tdap Vaccines Sales Quantity by Application (2025-2030) & (K Units)
Table 102. Europe DTaP and Tdap Vaccines Sales Quantity by Country (2019-2024) & (K Units)
Table 103. Europe DTaP and Tdap Vaccines Sales Quantity by Country (2025-2030) & (K Units)
Table 104. Europe DTaP and Tdap Vaccines Consumption Value by Country (2019-2024) & (USD Million)
Table 105. Europe DTaP and Tdap Vaccines Consumption Value by Country (2025-2030) & (USD Million)
Table 106. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Type (2019-2024) & (K Units)
Table 107. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Type (2025-2030) & (K Units)
Table 108. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Application (2019-2024) & (K Units)
Table 109. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Application (2025-2030) & (K Units)
Table 110. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Region (2019-2024) & (K Units)
Table 111. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Region (2025-2030) & (K Units)
Table 112. Asia-Pacific DTaP and Tdap Vaccines Consumption Value by Region (2019-2024) & (USD Million)
Table 113. Asia-Pacific DTaP and Tdap Vaccines Consumption Value by Region (2025-2030) & (USD Million)
Table 114. South America DTaP and Tdap Vaccines Sales Quantity by Type (2019-2024) & (K Units)
Table 115. South America DTaP and Tdap Vaccines Sales Quantity by Type (2025-2030) & (K Units)
Table 116. South America DTaP and Tdap Vaccines Sales Quantity by Application (2019-2024) & (K Units)
Table 117. South America DTaP and Tdap Vaccines Sales Quantity by Application (2025-2030) & (K Units)
Table 118. South America DTaP and Tdap Vaccines Sales Quantity by Country (2019-2024) & (K Units)
Table 119. South America DTaP and Tdap Vaccines Sales Quantity by Country (2025-2030) & (K Units)
Table 120. South America DTaP and Tdap Vaccines Consumption Value by Country (2019-2024) & (USD Million)
Table 121. South America DTaP and Tdap Vaccines Consumption Value by Country (2025-2030) & (USD Million)
Table 122. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Type (2019-2024) & (K Units)
Table 123. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Type (2025-2030) & (K Units)
Table 124. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Application (2019-2024) & (K Units)
Table 125. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Application (2025-2030) & (K Units)
Table 126. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Region (2019-2024) & (K Units)
Table 127. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Region (2025-2030) & (K Units)
Table 128. Middle East & Africa DTaP and Tdap Vaccines Consumption Value by Region (2019-2024) & (USD Million)
Table 129. Middle East & Africa DTaP and Tdap Vaccines Consumption Value by Region (2025-2030) & (USD Million)
Table 130. DTaP and Tdap Vaccines Raw Material
Table 131. Key Manufacturers of DTaP and Tdap Vaccines Raw Materials
Table 132. DTaP and Tdap Vaccines Typical Distributors
Table 133. DTaP and Tdap Vaccines Typical Customers
Table 1. Global DTaP and Tdap Vaccines Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global DTaP and Tdap Vaccines Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi Pasteur Major Business
Table 5. Sanofi Pasteur DTaP and Tdap Vaccines Product and Services
Table 6. Sanofi Pasteur DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Sanofi Pasteur Recent Developments/Updates
Table 8. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 9. GlaxoSmithKline Major Business
Table 10. GlaxoSmithKline DTaP and Tdap Vaccines Product and Services
Table 11. GlaxoSmithKline DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. GlaxoSmithKline Recent Developments/Updates
Table 13. Protein Sciences Corporation Basic Information, Manufacturing Base and Competitors
Table 14. Protein Sciences Corporation Major Business
Table 15. Protein Sciences Corporation DTaP and Tdap Vaccines Product and Services
Table 16. Protein Sciences Corporation DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Protein Sciences Corporation Recent Developments/Updates
Table 18. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 19. Novartis AG Major Business
Table 20. Novartis AG DTaP and Tdap Vaccines Product and Services
Table 21. Novartis AG DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Novartis AG Recent Developments/Updates
Table 23. Seqirus Basic Information, Manufacturing Base and Competitors
Table 24. Seqirus Major Business
Table 25. Seqirus DTaP and Tdap Vaccines Product and Services
Table 26. Seqirus DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Seqirus Recent Developments/Updates
Table 28. Merck Sharp & Dohme Corp Basic Information, Manufacturing Base and Competitors
Table 29. Merck Sharp & Dohme Corp Major Business
Table 30. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product and Services
Table 31. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Merck Sharp & Dohme Corp Recent Developments/Updates
Table 33. Astellas Pharma US, Inc Basic Information, Manufacturing Base and Competitors
Table 34. Astellas Pharma US, Inc Major Business
Table 35. Astellas Pharma US, Inc DTaP and Tdap Vaccines Product and Services
Table 36. Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Astellas Pharma US, Inc Recent Developments/Updates
Table 38. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 39. Pfizer Inc Major Business
Table 40. Pfizer Inc DTaP and Tdap Vaccines Product and Services
Table 41. Pfizer Inc DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Pfizer Inc Recent Developments/Updates
Table 43. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 44. Johnson & Johnson Major Business
Table 45. Johnson & Johnson DTaP and Tdap Vaccines Product and Services
Table 46. Johnson & Johnson DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Johnson & Johnson Recent Developments/Updates
Table 48. Lanzhou Institute of Biological Products Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 49. Lanzhou Institute of Biological Products Co., Ltd Major Business
Table 50. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product and Services
Table 51. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
Table 53. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 54. AstraZeneca Major Business
Table 55. AstraZeneca DTaP and Tdap Vaccines Product and Services
Table 56. AstraZeneca DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 57. AstraZeneca Recent Developments/Updates
Table 58. Emergent BioSolutions Inc Basic Information, Manufacturing Base and Competitors
Table 59. Emergent BioSolutions Inc Major Business
Table 60. Emergent BioSolutions Inc DTaP and Tdap Vaccines Product and Services
Table 61. Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 62. Emergent BioSolutions Inc Recent Developments/Updates
Table 63. Global DTaP and Tdap Vaccines Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 64. Global DTaP and Tdap Vaccines Revenue by Manufacturer (2019-2024) & (USD Million)
Table 65. Global DTaP and Tdap Vaccines Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 66. Market Position of Manufacturers in DTaP and Tdap Vaccines, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 67. Head Office and DTaP and Tdap Vaccines Production Site of Key Manufacturer
Table 68. DTaP and Tdap Vaccines Market: Company Product Type Footprint
Table 69. DTaP and Tdap Vaccines Market: Company Product Application Footprint
Table 70. DTaP and Tdap Vaccines New Market Entrants and Barriers to Market Entry
Table 71. DTaP and Tdap Vaccines Mergers, Acquisition, Agreements, and Collaborations
Table 72. Global DTaP and Tdap Vaccines Sales Quantity by Region (2019-2024) & (K Units)
Table 73. Global DTaP and Tdap Vaccines Sales Quantity by Region (2025-2030) & (K Units)
Table 74. Global DTaP and Tdap Vaccines Consumption Value by Region (2019-2024) & (USD Million)
Table 75. Global DTaP and Tdap Vaccines Consumption Value by Region (2025-2030) & (USD Million)
Table 76. Global DTaP and Tdap Vaccines Average Price by Region (2019-2024) & (USD/Unit)
Table 77. Global DTaP and Tdap Vaccines Average Price by Region (2025-2030) & (USD/Unit)
Table 78. Global DTaP and Tdap Vaccines Sales Quantity by Type (2019-2024) & (K Units)
Table 79. Global DTaP and Tdap Vaccines Sales Quantity by Type (2025-2030) & (K Units)
Table 80. Global DTaP and Tdap Vaccines Consumption Value by Type (2019-2024) & (USD Million)
Table 81. Global DTaP and Tdap Vaccines Consumption Value by Type (2025-2030) & (USD Million)
Table 82. Global DTaP and Tdap Vaccines Average Price by Type (2019-2024) & (USD/Unit)
Table 83. Global DTaP and Tdap Vaccines Average Price by Type (2025-2030) & (USD/Unit)
Table 84. Global DTaP and Tdap Vaccines Sales Quantity by Application (2019-2024) & (K Units)
Table 85. Global DTaP and Tdap Vaccines Sales Quantity by Application (2025-2030) & (K Units)
Table 86. Global DTaP and Tdap Vaccines Consumption Value by Application (2019-2024) & (USD Million)
Table 87. Global DTaP and Tdap Vaccines Consumption Value by Application (2025-2030) & (USD Million)
Table 88. Global DTaP and Tdap Vaccines Average Price by Application (2019-2024) & (USD/Unit)
Table 89. Global DTaP and Tdap Vaccines Average Price by Application (2025-2030) & (USD/Unit)
Table 90. North America DTaP and Tdap Vaccines Sales Quantity by Type (2019-2024) & (K Units)
Table 91. North America DTaP and Tdap Vaccines Sales Quantity by Type (2025-2030) & (K Units)
Table 92. North America DTaP and Tdap Vaccines Sales Quantity by Application (2019-2024) & (K Units)
Table 93. North America DTaP and Tdap Vaccines Sales Quantity by Application (2025-2030) & (K Units)
Table 94. North America DTaP and Tdap Vaccines Sales Quantity by Country (2019-2024) & (K Units)
Table 95. North America DTaP and Tdap Vaccines Sales Quantity by Country (2025-2030) & (K Units)
Table 96. North America DTaP and Tdap Vaccines Consumption Value by Country (2019-2024) & (USD Million)
Table 97. North America DTaP and Tdap Vaccines Consumption Value by Country (2025-2030) & (USD Million)
Table 98. Europe DTaP and Tdap Vaccines Sales Quantity by Type (2019-2024) & (K Units)
Table 99. Europe DTaP and Tdap Vaccines Sales Quantity by Type (2025-2030) & (K Units)
Table 100. Europe DTaP and Tdap Vaccines Sales Quantity by Application (2019-2024) & (K Units)
Table 101. Europe DTaP and Tdap Vaccines Sales Quantity by Application (2025-2030) & (K Units)
Table 102. Europe DTaP and Tdap Vaccines Sales Quantity by Country (2019-2024) & (K Units)
Table 103. Europe DTaP and Tdap Vaccines Sales Quantity by Country (2025-2030) & (K Units)
Table 104. Europe DTaP and Tdap Vaccines Consumption Value by Country (2019-2024) & (USD Million)
Table 105. Europe DTaP and Tdap Vaccines Consumption Value by Country (2025-2030) & (USD Million)
Table 106. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Type (2019-2024) & (K Units)
Table 107. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Type (2025-2030) & (K Units)
Table 108. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Application (2019-2024) & (K Units)
Table 109. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Application (2025-2030) & (K Units)
Table 110. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Region (2019-2024) & (K Units)
Table 111. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity by Region (2025-2030) & (K Units)
Table 112. Asia-Pacific DTaP and Tdap Vaccines Consumption Value by Region (2019-2024) & (USD Million)
Table 113. Asia-Pacific DTaP and Tdap Vaccines Consumption Value by Region (2025-2030) & (USD Million)
Table 114. South America DTaP and Tdap Vaccines Sales Quantity by Type (2019-2024) & (K Units)
Table 115. South America DTaP and Tdap Vaccines Sales Quantity by Type (2025-2030) & (K Units)
Table 116. South America DTaP and Tdap Vaccines Sales Quantity by Application (2019-2024) & (K Units)
Table 117. South America DTaP and Tdap Vaccines Sales Quantity by Application (2025-2030) & (K Units)
Table 118. South America DTaP and Tdap Vaccines Sales Quantity by Country (2019-2024) & (K Units)
Table 119. South America DTaP and Tdap Vaccines Sales Quantity by Country (2025-2030) & (K Units)
Table 120. South America DTaP and Tdap Vaccines Consumption Value by Country (2019-2024) & (USD Million)
Table 121. South America DTaP and Tdap Vaccines Consumption Value by Country (2025-2030) & (USD Million)
Table 122. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Type (2019-2024) & (K Units)
Table 123. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Type (2025-2030) & (K Units)
Table 124. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Application (2019-2024) & (K Units)
Table 125. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Application (2025-2030) & (K Units)
Table 126. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Region (2019-2024) & (K Units)
Table 127. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity by Region (2025-2030) & (K Units)
Table 128. Middle East & Africa DTaP and Tdap Vaccines Consumption Value by Region (2019-2024) & (USD Million)
Table 129. Middle East & Africa DTaP and Tdap Vaccines Consumption Value by Region (2025-2030) & (USD Million)
Table 130. DTaP and Tdap Vaccines Raw Material
Table 131. Key Manufacturers of DTaP and Tdap Vaccines Raw Materials
Table 132. DTaP and Tdap Vaccines Typical Distributors
Table 133. DTaP and Tdap Vaccines Typical Customers
LIST OF FIGURES
Figure 1. DTaP and Tdap Vaccines Picture
Figure 2. Global DTaP and Tdap Vaccines Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global DTaP and Tdap Vaccines Consumption Value Market Share by Type in 2023
Figure 4. DTaP Examples
Figure 5. Td Examples
Figure 6. Tdap Examples
Figure 7. Global DTaP and Tdap Vaccines Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global DTaP and Tdap Vaccines Consumption Value Market Share by Application in 2023
Figure 9. Adult Examples
Figure 10. Pediatric Examples
Figure 11. Global DTaP and Tdap Vaccines Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 12. Global DTaP and Tdap Vaccines Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 13. Global DTaP and Tdap Vaccines Sales Quantity (2019-2030) & (K Units)
Figure 14. Global DTaP and Tdap Vaccines Average Price (2019-2030) & (USD/Unit)
Figure 15. Global DTaP and Tdap Vaccines Sales Quantity Market Share by Manufacturer in 2023
Figure 16. Global DTaP and Tdap Vaccines Consumption Value Market Share by Manufacturer in 2023
Figure 17. Producer Shipments of DTaP and Tdap Vaccines by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 18. Top 3 DTaP and Tdap Vaccines Manufacturer (Consumption Value) Market Share in 2023
Figure 19. Top 6 DTaP and Tdap Vaccines Manufacturer (Consumption Value) Market Share in 2023
Figure 20. Global DTaP and Tdap Vaccines Sales Quantity Market Share by Region (2019-2030)
Figure 21. Global DTaP and Tdap Vaccines Consumption Value Market Share by Region (2019-2030)
Figure 22. North America DTaP and Tdap Vaccines Consumption Value (2019-2030) & (USD Million)
Figure 23. Europe DTaP and Tdap Vaccines Consumption Value (2019-2030) & (USD Million)
Figure 24. Asia-Pacific DTaP and Tdap Vaccines Consumption Value (2019-2030) & (USD Million)
Figure 25. South America DTaP and Tdap Vaccines Consumption Value (2019-2030) & (USD Million)
Figure 26. Middle East & Africa DTaP and Tdap Vaccines Consumption Value (2019-2030) & (USD Million)
Figure 27. Global DTaP and Tdap Vaccines Sales Quantity Market Share by Type (2019-2030)
Figure 28. Global DTaP and Tdap Vaccines Consumption Value Market Share by Type (2019-2030)
Figure 29. Global DTaP and Tdap Vaccines Average Price by Type (2019-2030) & (USD/Unit)
Figure 30. Global DTaP and Tdap Vaccines Sales Quantity Market Share by Application (2019-2030)
Figure 31. Global DTaP and Tdap Vaccines Consumption Value Market Share by Application (2019-2030)
Figure 32. Global DTaP and Tdap Vaccines Average Price by Application (2019-2030) & (USD/Unit)
Figure 33. North America DTaP and Tdap Vaccines Sales Quantity Market Share by Type (2019-2030)
Figure 34. North America DTaP and Tdap Vaccines Sales Quantity Market Share by Application (2019-2030)
Figure 35. North America DTaP and Tdap Vaccines Sales Quantity Market Share by Country (2019-2030)
Figure 36. North America DTaP and Tdap Vaccines Consumption Value Market Share by Country (2019-2030)
Figure 37. United States DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 38. Canada DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 39. Mexico DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Europe DTaP and Tdap Vaccines Sales Quantity Market Share by Type (2019-2030)
Figure 41. Europe DTaP and Tdap Vaccines Sales Quantity Market Share by Application (2019-2030)
Figure 42. Europe DTaP and Tdap Vaccines Sales Quantity Market Share by Country (2019-2030)
Figure 43. Europe DTaP and Tdap Vaccines Consumption Value Market Share by Country (2019-2030)
Figure 44. Germany DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 45. France DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. United Kingdom DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. Russia DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. Italy DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity Market Share by Type (2019-2030)
Figure 50. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity Market Share by Application (2019-2030)
Figure 51. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity Market Share by Region (2019-2030)
Figure 52. Asia-Pacific DTaP and Tdap Vaccines Consumption Value Market Share by Region (2019-2030)
Figure 53. China DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 54. Japan DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. Korea DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. India DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Southeast Asia DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Australia DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. South America DTaP and Tdap Vaccines Sales Quantity Market Share by Type (2019-2030)
Figure 60. South America DTaP and Tdap Vaccines Sales Quantity Market Share by Application (2019-2030)
Figure 61. South America DTaP and Tdap Vaccines Sales Quantity Market Share by Country (2019-2030)
Figure 62. South America DTaP and Tdap Vaccines Consumption Value Market Share by Country (2019-2030)
Figure 63. Brazil DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 64. Argentina DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 65. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity Market Share by Type (2019-2030)
Figure 66. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity Market Share by Application (2019-2030)
Figure 67. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity Market Share by Region (2019-2030)
Figure 68. Middle East & Africa DTaP and Tdap Vaccines Consumption Value Market Share by Region (2019-2030)
Figure 69. Turkey DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 70. Egypt DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. Saudi Arabia DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. South Africa DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. DTaP and Tdap Vaccines Market Drivers
Figure 74. DTaP and Tdap Vaccines Market Restraints
Figure 75. DTaP and Tdap Vaccines Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of DTaP and Tdap Vaccines in 2023
Figure 78. Manufacturing Process Analysis of DTaP and Tdap Vaccines
Figure 79. DTaP and Tdap Vaccines Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
Figure 1. DTaP and Tdap Vaccines Picture
Figure 2. Global DTaP and Tdap Vaccines Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global DTaP and Tdap Vaccines Consumption Value Market Share by Type in 2023
Figure 4. DTaP Examples
Figure 5. Td Examples
Figure 6. Tdap Examples
Figure 7. Global DTaP and Tdap Vaccines Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global DTaP and Tdap Vaccines Consumption Value Market Share by Application in 2023
Figure 9. Adult Examples
Figure 10. Pediatric Examples
Figure 11. Global DTaP and Tdap Vaccines Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 12. Global DTaP and Tdap Vaccines Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 13. Global DTaP and Tdap Vaccines Sales Quantity (2019-2030) & (K Units)
Figure 14. Global DTaP and Tdap Vaccines Average Price (2019-2030) & (USD/Unit)
Figure 15. Global DTaP and Tdap Vaccines Sales Quantity Market Share by Manufacturer in 2023
Figure 16. Global DTaP and Tdap Vaccines Consumption Value Market Share by Manufacturer in 2023
Figure 17. Producer Shipments of DTaP and Tdap Vaccines by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 18. Top 3 DTaP and Tdap Vaccines Manufacturer (Consumption Value) Market Share in 2023
Figure 19. Top 6 DTaP and Tdap Vaccines Manufacturer (Consumption Value) Market Share in 2023
Figure 20. Global DTaP and Tdap Vaccines Sales Quantity Market Share by Region (2019-2030)
Figure 21. Global DTaP and Tdap Vaccines Consumption Value Market Share by Region (2019-2030)
Figure 22. North America DTaP and Tdap Vaccines Consumption Value (2019-2030) & (USD Million)
Figure 23. Europe DTaP and Tdap Vaccines Consumption Value (2019-2030) & (USD Million)
Figure 24. Asia-Pacific DTaP and Tdap Vaccines Consumption Value (2019-2030) & (USD Million)
Figure 25. South America DTaP and Tdap Vaccines Consumption Value (2019-2030) & (USD Million)
Figure 26. Middle East & Africa DTaP and Tdap Vaccines Consumption Value (2019-2030) & (USD Million)
Figure 27. Global DTaP and Tdap Vaccines Sales Quantity Market Share by Type (2019-2030)
Figure 28. Global DTaP and Tdap Vaccines Consumption Value Market Share by Type (2019-2030)
Figure 29. Global DTaP and Tdap Vaccines Average Price by Type (2019-2030) & (USD/Unit)
Figure 30. Global DTaP and Tdap Vaccines Sales Quantity Market Share by Application (2019-2030)
Figure 31. Global DTaP and Tdap Vaccines Consumption Value Market Share by Application (2019-2030)
Figure 32. Global DTaP and Tdap Vaccines Average Price by Application (2019-2030) & (USD/Unit)
Figure 33. North America DTaP and Tdap Vaccines Sales Quantity Market Share by Type (2019-2030)
Figure 34. North America DTaP and Tdap Vaccines Sales Quantity Market Share by Application (2019-2030)
Figure 35. North America DTaP and Tdap Vaccines Sales Quantity Market Share by Country (2019-2030)
Figure 36. North America DTaP and Tdap Vaccines Consumption Value Market Share by Country (2019-2030)
Figure 37. United States DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 38. Canada DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 39. Mexico DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Europe DTaP and Tdap Vaccines Sales Quantity Market Share by Type (2019-2030)
Figure 41. Europe DTaP and Tdap Vaccines Sales Quantity Market Share by Application (2019-2030)
Figure 42. Europe DTaP and Tdap Vaccines Sales Quantity Market Share by Country (2019-2030)
Figure 43. Europe DTaP and Tdap Vaccines Consumption Value Market Share by Country (2019-2030)
Figure 44. Germany DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 45. France DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. United Kingdom DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. Russia DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. Italy DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity Market Share by Type (2019-2030)
Figure 50. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity Market Share by Application (2019-2030)
Figure 51. Asia-Pacific DTaP and Tdap Vaccines Sales Quantity Market Share by Region (2019-2030)
Figure 52. Asia-Pacific DTaP and Tdap Vaccines Consumption Value Market Share by Region (2019-2030)
Figure 53. China DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 54. Japan DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. Korea DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. India DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Southeast Asia DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Australia DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. South America DTaP and Tdap Vaccines Sales Quantity Market Share by Type (2019-2030)
Figure 60. South America DTaP and Tdap Vaccines Sales Quantity Market Share by Application (2019-2030)
Figure 61. South America DTaP and Tdap Vaccines Sales Quantity Market Share by Country (2019-2030)
Figure 62. South America DTaP and Tdap Vaccines Consumption Value Market Share by Country (2019-2030)
Figure 63. Brazil DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 64. Argentina DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 65. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity Market Share by Type (2019-2030)
Figure 66. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity Market Share by Application (2019-2030)
Figure 67. Middle East & Africa DTaP and Tdap Vaccines Sales Quantity Market Share by Region (2019-2030)
Figure 68. Middle East & Africa DTaP and Tdap Vaccines Consumption Value Market Share by Region (2019-2030)
Figure 69. Turkey DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 70. Egypt DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. Saudi Arabia DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. South Africa DTaP and Tdap Vaccines Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. DTaP and Tdap Vaccines Market Drivers
Figure 74. DTaP and Tdap Vaccines Market Restraints
Figure 75. DTaP and Tdap Vaccines Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of DTaP and Tdap Vaccines in 2023
Figure 78. Manufacturing Process Analysis of DTaP and Tdap Vaccines
Figure 79. DTaP and Tdap Vaccines Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
